• Ceolin L, Bortolotto ZA, Bannister N, Collingridge GL, Lodge D, Volianskis A. (2012) A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int 61:517522.
  • European Medicines Agency. (2012) Fycompa summary of product characteristics.
  • Food and Drug Administration. (2012) Fycompa prescribing information.
  • Franco V, Crema F, Iudice A, Zaccara G, Grillo E. (2013) Novel treatment options for epilepsy: focus on perampanel. Pharmacol Res 70:3540.
  • French JA. (2007) Refractory epilepsy: clinical overview. Epilepsia 48(Suppl. 1):37.
  • French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, Kumar D, Rogawski MA. (2012) Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 79:589596.
  • French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, Laurenza A. (2013) Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global Phase III study 305. Epilepsia 54:117125.
  • Fuseau E, Templeton D, Hussein Z. (2011) Population pharmacokinetics and pharmacodynamics of perampanel in patients with refractory partial seizures. Epilepsy Curr 11(Suppl. 1):abs 1.264.
  • Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, Hatakeyama S, Ohgoh M, Ueno M, Nishizawa Y. (2011) Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 52:13311340.
  • Johannessen SI, Landmark CJ. (2010) Antiepileptic drug interactions – principles and clinical implications. Curr Neuropharmacol 8:254267.
  • Kramer L, Perucca E, Ben-Menachem E, Kwan P, Shih J, Squillacote D, Yang H, Zhu J, Laurenza A. (2012) Perampanel, a selective, non-competitive AMPA receptor antagonist, as adjunctive therapy in patients with refractory partial-onset seizures: a dose–response analysis from Phase III studies. Neurology 78(Suppl. 1):P06.117.
  • Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene-Magistris N, Squillacote D, Kumar D. (2012a) Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 125:815.
  • Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J, Yang H, Squillacote D, Edwards HB, Zhu J, Laurenza A. (2012b) Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 78:14081415.
  • Laurenza A, Ferry J, Hussein Z. (2012) Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials. Epilepsy Curr 12(Suppl. 1):abs 2.231.
  • Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. (2008) Antiepileptic drugs–best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49:12391276.
  • Perucca E, Tomson T. (2011) The pharmacological treatment of epilepsy in adults. Lancet Neurol 10:446456.
  • Rektor I. (2013) Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures. Expert Opin Pharmacother 14:225235.
  • Templeton D. (2009) Pharmacokinetics of perampanel, a highly selective AMPA-type glutamate receptor antagonist. Epilepsia 50(Suppl. 11):abs 1.199.